<DOC>
	<DOCNO>NCT02492217</DOCNO>
	<brief_summary>To identify new candidate gene proteins differentially express responder ' vs non-responders anti-TNF alpha therapy several time point investigator use transcriptomic proteomic analysis . Demonstrate link gene expression protein marker regard prediction anti-TNF alpha therapy efficacy .</brief_summary>
	<brief_title>Biomarkers Identification Anti-tumor Necrosis Factor ( TNF ) α Agent 's Efficacy Ankylosing Spondylitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>AS accord Portuguese Society Rheumatology ( SPR ) guideline ( 1984 modify New York Criteria , allow use MRI imagiological criterion ) Patient enrolment follow national guideline TNF antagonist use treatment AS Adults 18 75 year Ability provide inform consent Corticosteroid therapy allow ( equivalent ≤ 10 mg prednisone ) / NSAID ( nonsteroidal antiinflammatory drug ) , stable dose 4 week study initiation Adequate contraception ( barrier hormonal ) men woman childbearing age ( patient partner Adequate renal hepatic function ( 2 time ULN ) Current pregnancy breastfeed Previous treatment biologic DMARD 's ( diseasemodifying antirheumatic drug ) Intraarticular injection infiltration extraaxial joint tendon within 28 day screen , intraarticular injection sacroiliac joint ≤ 28 day screen History rheumatic disorder AS Other form spondylarthritis AS Any uncontrolled medical condition ( e.g. , uncontrolled diabetes mellitus , unstable ischemic heart disease ) History sign demyelinate disease Malignancy ( except completely treat squamous basal cell carcinoma ) Moderate severe heart failure ( NYHA class III/IV ) Positive serology hepatitis B , hepatitis C , human immunodeficiency virus Active latent tuberculosis ( TB ) histoplasmosis severe infection sepsis , opportunistic infection Infections require hospitalization intravenous treatment antibiotic within 30 day oral treatment antibiotic within 14 day enrollment Ankylosis spine ( syndesmophytes presence level D12 S1 Xray ( XR ) lateral view ) Hypersensitivity active substance excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>adalimumab</keyword>
	<keyword>TNF-alpha agent</keyword>
	<keyword>spondyloarthritis</keyword>
	<keyword>biologic therapy</keyword>
	<keyword>AS</keyword>
	<keyword>biomarkers</keyword>
	<keyword>efficacy prediction</keyword>
</DOC>